Safety analyses from the phase 3 ascent trial of sacituzumab govitecan in metastatic triple-negative breast cancer

HIGHLIGHTS

• who: Hope S. Rugo from the (UNIVERSITY) have published the Article: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer, in the Journal: (JOURNAL) of March/11,/2020
• what: The study was approved by each institutional review board or ethics committee prior to initiation and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines per the International Conference on Harmonization.

SUMMARY

Triple-negative breast cancer (TNBC) comprises approximately 15% of all breast cancers and is associated with a . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.